P. Nagy

发表

Prevention of Relapse of Healed Reflux Esophagitis is Related to the Duration of Intragastric pH>4

D. Levine, M. Åstrand, D. Johnson, 2010, Journal of clinical gastroenterology.

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

D. Levine, M. Åstrand, P. Katz, 2010, Alimentary pharmacology & therapeutics.

Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

T. Andersson, L. Wallentin, P. Nagy, 2014, American Journal of Cardiovascular Drugs.

Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials

D. Johnson, P. Nagy, A. Le Moigne, 2015, Current medical research and opinion.

Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81 mg With or Without Esomeprazole 20 mg in Healthy Volunteers

T. Andersson, T. Warner, P. Nagy, 2012, American Journal of Cardiovascular Drugs.

Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection: The OBERON Trial

Á. Lanas, S. Agewall, J. Herlitz, 2013, Journal of cardiovascular pharmacology.

Patterns in the Use of Low-Dose Acetylsalicylic Acid and Other Therapies Following Upper Gastrointestinal Bleeding

S. Johansson, L. G. García Rodríguez, A. Gonzáléz-Pérez, 2014, American Journal of Cardiovascular Drugs.

Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.

A. Forbes, D. Armstrong, D. Seidner, 2020, Clinical nutrition.

Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events

S. Johansson, M. Martín-Pérez, A. Ruigómez, 2014, BMC Gastroenterology.

Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial

C. Ell, J. Galmiche, L. Lundell, 2015, Current medical research and opinion.

Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event

S. Johansson, A. Gonzáléz-Pérez, P. Nagy, 2015, Journal of cardiovascular pharmacology and therapeutics.

Represcription of Low-Dose Acetylsalicylic Acid After Discontinuation in Patients Receiving Treatment for Secondary Cardiovascular Disease Prevention in the UK

S. Johansson, E. Martín-Merino, P. Nagy, 2014, American Journal of Cardiovascular Drugs.

Role of Tachykinin 1 and 4 Gene-Derived Neuropeptides and the Neurokinin 1 Receptor in Adjuvant-Induced Chronic Arthritis of the Mouse

J. Stewart, J. Quinn, A. Zimmer, 2013, PloS one.

Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients

P. Malfertheiner, M. Stolte, L. Engstrand, 2008, European journal of gastroenterology & hepatology.

Effect of esomeprazole on gastroduodenal erosions in patients at increased gastrointestinal risk treated with low-dose acetylsalicylic acid: a post-hoc analysis of the OBERON trial.

Á. Lanas, J. Scheiman, S. Veldhuyzen van Zanten, 2015, International journal of cardiology.

A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction

C. Pollack, D. Peura, T. Lind, 2016, Postgraduate medicine.

Original article Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20mg in two randomized, double-blind, controlled trials

D. Johnson, P. Nagy, Vincent Hugo, 2015 .

Risk Factors Associated with Uncomplicated Peptic Ulcer and Changes in Medication Use after Diagnosis

S. Johansson, L. G. García Rodríguez, A. Gonzáléz-Pérez, 2014, PloS one.

Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study

T. Hibi, T. Yajima, T. Yokoyama, 2017, Inflammatory Intestinal Diseases.

Systematic review: the effects of long‐term proton pump inhibitor use on serum gastrin levels and gastric histology

M. Vieth, L. Lundell, P. Kahrilas, 2015, Alimentary pharmacology & therapeutics.

The effects of dose and timing of esomeprazole administration on 24‐h, daytime and night‐time acid inhibition in healthy volunteers

K. Röhss, P. Nagy, M. Sagar, 2010, Alimentary pharmacology & therapeutics.

Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists

E. Kuipers, R. Herings, S. Johansson, 2018, Current medical research and opinion.

Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study

S. Johansson, L. G. García Rodríguez, A. Ruigómez, 2017, Current medical research and opinion.

Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care

S. Johansson, P. Nagy, Luis A. Rodriguez, 2013, Thrombosis and Haemostasis.

Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA

S. Johansson, P. Nagy, M. Molloy-Bland, 2016, Gut Pathogens.

Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers

Dongyang Liu, Ji Jiang, P. Hu, 2016, Journal of clinical pharmacology.

Risk of seizure associated with use of acid-suppressive drugs: An observational cohort study

S. Johansson, A. Gonzáléz-Pérez, P. Nagy, 2016, Epilepsy & Behavior.

Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo

D. Johnson, C. Pollack, P. Nagy, 2016, Clinical Drug Investigation.

Acid Control Cannot Be Improved with a Modified-Release Formulation of a Proton Pump Inhibitor Compared with Twice-Daily Dosing of the Conventional Formulation

C. Wilder-Smith, K. Röhss, P. Nagy, 2010, Digestive Diseases and Sciences.

Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers

P. Malfertheiner, B. C. Wong, M. Stolte, 2010, Scandinavian journal of gastroenterology.

Mortality in patients who discontinue low‐dose acetylsalicylic acid therapy after upper gastrointestinal bleeding

S. Johansson, L. G. García Rodríguez, A. Gonzáléz-Pérez, 2017, Pharmacoepidemiology and drug safety.

Patterns of antiplatelet therapy in patients who have experienced an acute coronary event: a descriptive study in primary care

S. Johansson, A. Gonzáléz-Pérez, P. Nagy, 2013 .

Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers.

T. Andersson, T. Warner, P. Nagy, 2012, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial

C. Ell, J. Galmiche, L. Lundell, 2015, Current Medical Research and Opinion.

Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.

S. Johansson, L. G. García Rodríguez, P. Nagy, 2013, The American journal of cardiology.